Vaccine-Elicited CD8+ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice

Sujin Lee, Emory University
Kate L. Stokes, Emory University
Michael G. Currier, Emory University
Kaori Sakamoto, University of Georgia
Nicholas W. Lukacs, University of Michigan
Esteban Celis, Moffitt Cancer Center
Martin L Moore, Emory University

Journal Title: Journal of Virology
Volume: Volume 86, Number 23
Publisher: American Society for Microbiology | 2012-12, Pages 13016-13024
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01770-12
Permanent URL: http://pid.emory.edu/ark:/25593/f4xw3

Final published version: http://jvi.asm.org/content/86/23/13016

Copyright information:
© 2012, American Society for Microbiology. All Rights Reserved.

Accessed June 15, 2020 10:28 AM EDT
Vaccine-Elicited CD8+ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice

Sujin Lee,a,b Kate L. Stokes,a,b Michael G. Currier,a,b Kaori Sakamoto,c Nicholas W. Lukacs,d Esteban Celis,e and Martin L. Moorea,b

CD8+ T cells may contribute to vaccines for respiratory syncytial virus (RSV). Compared to CD8+ T cells responding to RSV infection, vaccine-elicited anti-RSV CD8+ T cells are less well defined. We used a peptide vaccine to test the hypothesis that vaccine-elicited RSV-specific CD8+ T cells are protective against RSV pathogenesis. BALB/c mice were treated with a mixture (previously termed TriVax) of an M282-90 peptide representing an immunodominant CD8 epitope, the Toll-like receptor (TLR) agonist poly(I-C), and a costimulatory anti-CD40 antibody. TriVax vaccination induced potent effector anti-RSV CD8+ cytotoxic T lymphocytes (CTL). Mice were challenged with RSV strain A2-line19F, a model of RSV pathogenesis leading to airway mucin expression. Mice were protected against RSV infection and against RSV-induced airway mucin expression and cellular lung inflammation when challenged 6 days after vaccination. Compared to A2-line19F infection alone, TriVax vaccination followed by challenge resulted in effector CD8+ T cells with greater cytokine expression and the more rapid appearance of RSV-specific CD8+ T cells in the lung. When challenged 42 days after TriVax vaccination, memory CD8+ T cells were elicited with RSV-specific tetramer responses equivalent to TriVax-induced effector CD8+ T cells. These memory CD8+ T cells had lower cytokine expression than effector CD8+ T cells, and protection against A2-line19F was partial during the memory phase. We found that vaccine-elicited effector anti-RSV CD8+ T cells protected mice against RSV infection and pathogenesis, and waning protection correlated with reduced CD8+ T cell cytokine expression.

Respiratory syncytial virus (RSV) is the leading cause of viral lower respiratory tract illness in infants. RSV causes morbidity and mortality in children and the elderly, including high rates of hospitalization in infants (17, 43). Despite efforts such as inactivated, live attenuated, subunit, viral-vector, and DNA vaccines, there is no approved RSV vaccine yet. It is well-known that anti-RSV neutralizing antibodies (Abs) are protective (50). However, inducing adequate titers of anti-RSV neutralizing antibodies at the mucosal surface by vaccination has proven elusive. It has been suggested that RSV vaccines that induce antibody and CD8+ T cells may be effective (22). Vaccines that elicit CD8+ T cell responses against cancer and viruses are being designed (14, 53). Elucidating T cell responses against RSV, our long-term goal, will advance RSV vaccines across vaccine platforms.

CD8+ T cells are central to RSV pathogenesis, but their role is still controversial. In mice, T cells mediate RSV clearance, augment weight loss, and contribute to lung pathology (11, 23). The CD8+ T cell response to RSV infection in BALB/c mice is characterized by a highly immunodominant epitope in the M2-1 protein, M282-90, followed by a subdominant epitope in the fusion (F) protein (13, 31, 34). The robust M282-90-specific CD8+ T cell response causes weight loss in RSV-infected mice and has thus been considered immunopathologic (48). On the other hand, M282-90-specific CD8+ T cells are protective in a mouse model of RSV glycoprotein (G)-primed vaccine-enhanced immunopathology (44). Importantly, there is no evidence that CD8+ T cells enhance RSV disease severity in humans (54). RSV-specific CD8+ T cells are found in the airways of infants, and the presence of CD8+ T cells correlates with convalescence, not illness (25, 35). Fatal RSV disease in infants was characterized by a lack of T cells in the lung in one study, while CD8+ T cells were noted in the lung infiltrate of a fatal RSV case in another study (28, 54). RSV inhibits T cell responses in mice and human cells. The interferon (IFN) antagonizing nonstructural proteins (NS1 and NS2) of RSV have the effect of suppressing CD8+ T cell activation and proliferation (29, 41). M282-90-specific CD8+ T cells in the lungs of BALB/c mice are relatively poor producers of gamma interferon (IFN-γ) (12). Due to viral immune modulation, phenotypic characterization of RSV-specific T cells in wild-type virus infection may underestimate the potential of these cells for vaccines.

Synthetic peptides of 8 to 10 residues representing a CD8+ T cell epitope are an attractive approach for eliciting antigen-defined, protective CD8+ T cells (18, 47). Administration of peptide in combination with a Toll-like receptor 3 (TLR3) ligand [poly(I-C)] and anti-CD40 monoclonal antibody (MAb) (termed “TriVax” by another group) results in the generation of significantly robust CD8+ T cell responses compared to other peptide vaccination strategies (3, 14). We evaluated the immunogenicity and antiviral effectiveness of TriVax vaccination in a viral model using RSV strain A2-line19F that expresses the fusion protein of the mucus-inducing RSV strain line 19 (40). Abundant mucus in the airways is a hallmark of severe RSV disease in infants (28). Infection of BALB/c mice with A2-line19F results in greater viral load, airway mucus, and lung dysfunction than laboratory A2 RSV strain, thus providing a more robust mouse model (40). In addition, we investigated whether TriVax vaccination can generate
long-lasting memory CD8+ T cell responses, because vaccination with CD8+ T cell-inducing RSV recombinant vaccinia virus generated only short-lived protective immunity (15, 16). Although generation of memory T cells is a hallmark for successful vaccination, duration of RSV-specific T cell responses elicited by vaccination is largely unknown.

We hypothesized that RSV-specific CD8+ T cells elicited by TriVax ameliorate rather than contribute to RSV disease severity. We demonstrate that TriVax vaccination successfully generated large-quantity and high-quality RSV-specific CD8+ T cells at the effector phase. RSV challenge of TriVax-vaccinated mice resulted in complete clearance of viral load at the effector phase and partial clearance at the memory phase. There was no evidence of immunopathology due to TriVax vaccination as measured by lung pathology, weight loss, and expression of mucin in airways. Additionally, we found that TriVax-induced memory CD8+ T cells were protective against RSV but not to the extent of TriVax-induced effector CD8+ T cells. These results advance our knowledge of the phenotypes and potential of RSV-specific CD8+ T cells elicited by vaccination.

MATERIALS AND METHODS

Mice and virus. Pathogen-free 6- to 8-week-old female BALB/c (H-2b) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All animal procedures were conducted according to the guidelines of the Emory University Institutional Animal Care and Use Committee. RSV 52-A2-line19 was generated as described previously (40).

Peptide, antibody, and tetramer. Synthetic peptides representing H-2Kd-restricted CD8+ T cell epitopes MA22-90 (SYIGSINNI) and F85-93 (KYKNAYTEL) were purchased from EZBiolab Inc. (Carmel, IN), and 20-ng/ml stock solutions were made in dimethyl sulfoxide (DMSO). The purity (≥95%) and identity of peptides were determined by analytic high-performance liquid chromatography by the manufacturer. Rat anti-mouse CD40 monoclonal antibody (anti-CD40 MAb; clone F1K4.5) was purchased from Bio X Cell (West Lebanon, NH). Biotinylated H-2Kd, MA22-90 monomer and phycoerythrin (PE)-H-2Kd-F85-93 tetramer were provided by the National Institute of Allergy and Infectious Diseases Tetramer Facility (Emory University, Atlanta, GA). MA22-90 tetramers were prepared by mixing the biotinylated MA22-90 monomers with streptavidin labeled with R-phycoerythrin (streptavidin-R-PE). Titration of tetramers was performed to determine optimal staining concentration.

Vaccination and infection. Mice were injected intravenously (i.v.) or intraperitoneally (i.p.) with a mixture of 200 μg peptide, 50 μg anti-CD40 MAb, and 50 μg poly(I-C) (Invivogen, San Diego, CA). As indicated, some mice were given a second identical TriVax treatment (2× TriVax) 2 weeks following the primary treatment. Mice were anesthetized by intramuscular injection of a ketamine-xylazine solution and injected intranasally with 2×10^6 PFU RSV recombinant A2-line19 (A2-line19) in 100 μl Eagle’s minimum essential medium (EMEM) at day 6 (effector phase) or day 42 (memory phase) following the last TriVax treatment.

Preparation of lung lymphocytes. Mice were euthanized by i.p. sodium pentobarbital (8.5 mg/kg body weight) at the time points indicated. The lungs were removed from the mice and placed in complete RPMI supplemented with 10% fetal bovine serum (FBS). The lung tissues were minced and ground through a sterile mesh to obtain a single-cell suspension. Cells were layered onto Fico/Lite-LM (mouse) (Atlanta Biologicals, Lawrenceville, GA), and lung mononuclear cells were isolated by centrifugation at 2,700 rpm.

Flow cytometry. For tetramer analysis, peripheral blood was collected from the submandibular vein, and red blood cells were lysed by treatment with ACK buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). Freshly isolated peripheral blood lymphocytes (PBLs) in fluorescein-activated cell sorting (FACS) buffer (10 ml FBS and 0.5 g sodium azide/500 ml PBS) were incubated with H-2Kd MA22-90 tetramer for 30 min at 4°C followed by surface staining for PerCP- and Cy5.5-labeled anti-CD3 (PerCP-Cy5.5-anti-CD3) and allophycocyanin (APC)- and Cy7-labeled anti-CD8 (APC-Cy7-anti-CD8). All antibodies listed were purchased from BD Biosciences (Franklin Lakes, NJ) or eBioscience (San Diego, CA). Singlet discrimination was sequentially performed by using plots for forward scatter (FSC) (forward scatter height [FSC-H] versus forward scatter width [FSC-W]) and side scatter (SSC) (SSC-W versus SSC-H), and dead cells were excluded by scatter characteristics. Flow cytometry was performed using an LSRII cytometer (BD Immunocytometry Systems). Data analysis was performed using FlowJo software (Tree Star, Ashland, OR).

ICS. To enumerate cytokine-producing cells, intracellular cytokine staining (ICS) was performed as previously described (34). Briefly, freshly isolated lung lymphocytes (5 × 10^6) were left untreated or stimulated with individual peptides (1 μg/sample) for 6 h at 37°C in 5% CO2, in the presence of Golgi-plug (BD Pharmingen, San Diego, CA). Prior to surface staining, cells were preincubated with 1 μg rat anti-mouse CD16/CD32 antibody (Bio X Cell, West Lebanon, NH) for 15 min at room temperature (RT) to inhibit nonspecific binding of immunoglobulins to Fc receptors. Cell surface staining was performed, followed by ICS using Cytofix/Cytoperm (BD Pharmingen, San Diego, CA) in accordance with the manufacturer’s protocol. Fluorescein isothiocyanate (FITC)-labeled anti-IFN-γ (FITC-anti-IFN-γ) (clone XMG1.2), phycoerythrin (PE)-labeled antibody against interleukin 2 (IL-2) (PE-anti-IL-2) (clone JES6-5H4), and allophycocyanin-labeled antibody against tumor necrosis factor alpha (TNF-α) (anti-TNF-α MAb) (clone MP6-XT22) along with surface markers PerCP-Cy5.5-anti-CD3 (clone 145-2C11) and APC-Cy7-anti-CD8 (clone 53-6.7) were used.

In vivo CTL assay. In vivo cytotoxic T lymphocyte (CTL) assay was performed as described previously (5). Naive splenocytes were unpulsed or pulsed with 1 μg MA22-90 peptide for 3 h at 37°C in a humidified incubator containing 5% CO2. Splenocytes were labeled with low (0.5 μM, unpulsed) and high (5 μM, pulsed with peptide) concentrations of carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Carlsbad, CA). Labeled splenocytes were coincubated i.v. in a 1:1 ratio (1 × 10^7 total cells in 100 μl of PBS) into naive and TriVax-treated mice. Mice were euthanized 18 h later, and CFSEhi and CFSElo cells in splenocytes were quantified by flow cytometry.

Plaque assay. Mice were euthanized day 4 postinfection (p.i.). We used a Beadlower (Biopetsc Products, Bartlesville, OK) to homogenize the lungs as described previously (51). Lung homogenates were immediately centrifuged to obtain subconfluent H1P-2 cells in 24-well plates. After 1-h adsorption at room temperature on a rocking platform, the cells were overlaid with minimum essential medium (MEM) containing 10% FBS, penicillin G, streptomycin sulfate, amphotericin B solution, and 0.75% methylcellulose. After 6 days, the overlay medium was removed, and the cells were fixed with methanol. Plaques were visualized by immunodetection as previously described (37, 51).

Histopathology. Heart-lung blocks were harvested at day 8 p.i. and fixed in 10% formalin overnight. Lungs were transferred to 70% ethanol and then embedded in paraffin blocks as described elsewhere (40, 51). Tissue sections (5 μm) were stained with hematoxylin and eosin (H&E) to assess histologic changes. Intestinal pneumonia (IP) scores were determined by a pathologist who was blinded to the experimental groups. Peribronchiolar and perivascular edema scores were also determined. Additional sections were stained with periodic acid–Schiff (PAS) stain for a measure of mucin expression. PAS-stained slides were digitally scanned using a Zeiss Mirax Midi microscope with a 20× objective having a 0.85 numerical aperture (Carl Zeiss Microimaging Inc., Thornwood, NY) (51). Each area of airway epithelium was annotated using HistoQuant software (3D Histech, Budapest, Hungary). PAS-positive areas within the airway epithelium were analyzed and identified by HistoQuant software as described previously (51).

Statistical analyses. P values were determined by either a two-tailed t test or one-way analysis of variance (ANOVA) and Tukey multiple com-
TriVax vaccination induces RSV-specific cytotoxic CD8+ T cells. The 1X and 2X TriVax vaccination protocols are illustrated (Fig. 1A). To investigate RSV-specific CD8+ T cell immune responses induced by TriVax, we tested two RSV epitopes, M2 82–90 (immunodominant) and F 85–93 (subdominant) (13, 31). Mice (n = 5) were vaccinated with either F 85–93 TriVax or M2 82–90 TriVax i.v. PBLs were isolated 6 days after 1X TriVax vaccination. Tetramer staining showed that 0.8% ± 0.1% of CD3+ CD8+ T cells were F 85–93 specific following vaccination with F 85–93 TriVax, and 5.9% ± 1.2% of CD3+ CD8+ T cells were M2 82–90 specific following vaccination with M2 82–90 TriVax (Fig. 1B). Next, to determine the most efficient route to evaluate TriVax vaccination, mice (n = 5) were vaccinated with M2 82–90 1X TriVax i.p. or i.v. We observed that after 1X TriVax vaccination of the mice, the percentage of M2 82–90-specific CD8+ T cells generated by the i.v. route was approximately 4-fold greater than the i.p. route (Fig. 1C). The i.v. route was therefore selected for further experiments. We used an in vivo CTL assay to quantify effector cytotoxic function mediated by TriVax-induced M2 82–90-specific CD8+ T cells (5). M2 82–90 pulsed target cells (CFSEHi; Fig. 1D, arrow) were undetectable 18 h after injection into 2X TriVax-vaccinated mice. However, CFSEHi target cells were present in unvaccinated naïve mice. TriVax vaccination successfully elicited RSV-specific CTL cytotoxicity. An immunodominant epitope, M2 82–90, used in this study is conserved among RSV strains, including lab strains such as A2, Long, and line 19, and largely conserved among clinical isolates (46).

Antiviral effect of TriVax vaccination at the effector phase. We performed RSV challenge experiments to define the antiviral potential of TriVax-induced CD8+ T cells at the effector phase. Naïve (n = 6) and 2X TriVax-vaccinated mice (n = 6) were challenged at day 6 postboost. 2X TriVax vaccination protected BALB/c mice from RSV A2-line 19F infection at the effector phase (Fig. 2A). Antigen (Ag)-specific CD8+ T cells are critical for RSV clearance (39). In order to investigate whether complete protection is correlated with increased RSV-specific CD8+ T cell immune responses, we measured RSV-specific CD8+ T cells infiltrating the lungs with M2 82–90 tetramers. Whereas we observed less than 4% tetramer-positive CD3+ CD8+ T cells in the nonvaccinated group, 50% of CD8+ T cells were tetramer positive in the 2X TriVax-vaccinated groups at day 4 p.i. (Fig. 2B). Thus, 2X TriVax vaccination resulted in the rapid appearance of M2 82–90-specific CD8+ T cells compared to infection. We measured weight loss during RSV infection as an indicator of RSV illness severity (23). No significant weight loss was detected in naïve or 2X TriVax-vaccinated groups over the time course (Fig. 2C). Taken together, RSV challenge during the effector phase of the response to TriVax resulted in protection against RSV infection that correlated with an improvement in airways was performed using SAS 9.2 (Cary, NC). Statistical significance was assessed at P < 0.05. Since the outcomes were proportions ranging from 0 to 1 and nonnormal, the arcsine transformation was used to normalize the data. Normality was assessed using normal probability plots and histograms. Repeated-measures ANOVA was used to determine the effect of treatment on the outcome ratio of mask area to field area of epithelium (rMA) using the proc mixed procedure in SAS.

RESULTS

TriVax induces robust, functional Ag-specific responses to RSV M2 82–90. (A) Experimental schedule for TriVax vaccination, RSV challenge, and assays. D0, day 0. (B) Enumeration of F 85–93-specific and M2 82–90-specific CD8+ T cells. BALB/c mice (five mice per group) were vaccinated once with either F 85–93 TriVax or M2 82–90 TriVax i.v. PBLs were isolated day 6 after vaccination. (Left) Representative dot plots show the percentage of CD3+ CD8+ T cells that were F 85–93 tetramer (Tet) positive or M2 82–90 tetramer positive. (Right) Mean percent tetramer-positive CD8+ T cells in PBLs plus standard error of the mean (SEM) (error bar). The two values were significantly different (P < 0.05) as indicated by the asterisk. (C) BALB/c mice (five mice per group) were vaccinated once with M2 82–90 TriVax i.p. or i.v. PBLs were isolated day 6 after vaccination. (Left) Numbers in the upper right quadrant gate of the dot plots represent the percentage of CD3+ CD8+ T cells that were tetramer positive. (Right) Percent tetramer-positive CD8+ T cells in PBLs plus SEM. The two values were significantly different (P < 0.05) as indicated by the asterisk. (D) In vivo M2 82–90-specific CTL activity was measured by injection of CFSE-labeled target cells at day 6 postboost (2X TriVax; n = 3). Splenocytes were isolated 18 h later, and M2 82–90 tetramer staining was performed. For a negative control, naïve mice (n = 3) were given CFSE-labeled target cells. CFSEHi target cells, which were not pulsed with M2 82–90 peptide, were an internal control. The black arrows indicate M2 82–90-Pulsed, CFSEHi target cells. Data shown represent one of three experiments with similar results.
Body weights were recorded daily. Data shown represent one of five experiments. Each experiment was done three times with similar results. The means ± standard errors of the means are shown.

**FIG 2.** TriVax efficacy at the effector phase. (A) BALB/c mice were vaccinated. At day 6 following 2X TriVax vaccination, mice (n = 6) were challenged with A2-line19F. Lungs were harvested day 4 p.i., and infectious RSV was titrated by plaque assay. Each symbol represents the value for an individual mouse, and the black bar represents the mean for the group of mice. The horizontal line depicts the limit of detection. (B) Enumeration of M282–90-specific CD8+ T lymphocytes after challenge. BALB/c mice (five mice per group) were challenged with A2-line19F at day 6 postboost. Lung lymphocytes were isolated on day 8 p.i. and stained with anti-CD3, anti-CD8, and M282–90 tetramer. (C) BALB/c mice (five mice per group) were unvaccinated or vaccinated with M282–90, 2X TriVax and challenged with RSV A2-line19F at day 6 postboost. Body weights were recorded daily. Data shown represent one of five experiments, all with similar results.

**TABLE 1** Kinetics of M282–90-specific CD8+ T cell responses in the lunga

<table>
<thead>
<tr>
<th>Group</th>
<th>Days p.i.</th>
<th>% Tet+ CD8+ cells</th>
<th>% IFN-γ+ CD8+ cells</th>
<th>Ratio of % IFN-γ+ cells to % Tet+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naive, challenged</td>
<td>4</td>
<td>1.1 ± 0.4</td>
<td>0.5 ± 0.2</td>
<td>43.4 ± 2.5d</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>27.0 ± 3.5</td>
<td>12.4 ± 1.8</td>
<td>45.8 ± 4.1c</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>38.7 ± 5.0</td>
<td>20.1 ± 2.7</td>
<td>51.9 ± 2.4c</td>
</tr>
<tr>
<td>2X TriVax-vaccinated, challenged</td>
<td>4</td>
<td>62.1 ± 4.8</td>
<td>51.4 ± 6.7</td>
<td>82.7 ± 10.8b</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>54.3 ± 2.9</td>
<td>44.5 ± 2.1</td>
<td>81.0 ± 4.3c</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>35.6 ± 5.1</td>
<td>33.2 ± 1.7</td>
<td>94.0 ± 9.6d</td>
</tr>
</tbody>
</table>

a BALB/c mice were unvaccinated (naive, challenged mice) (n = 5) or 2X TriVax vaccinated (n = 5) and challenged with A2-line19F. Lung lymphocytes were stained with M282–90 tetramer or with IFN-γ at days 4, 8, and 12 p.i. The ratio of the percentage of IFN-γ+ expressing cells to the percentage of M282–90 tetramer (Tet)+ positive cells was calculated. All data represent the results of one experiment. Each experiment was done three times with similar results. The means ± standard errors of the means are shown.

b These two values are significantly different (P < 0.01).

c These two values are significantly different (P < 0.001).

d These two values are significantly different (P < 0.01).
In quadrant gates represent the percentages of CD3+ CD8+ T cells after challenge. BALB/c mice (five mice per group) were unvaccinated or vaccinated with M282–90 2X TriVax and challenged with RSV A2-line19F at day 6 postboost. Lung lymphocytes were isolated on day 8 p.i. and incubated in the presence (M282–90 [1 μg/sample]) or absence (un) of the M282–90 peptide. Dot plots show where the numbers in quadrant gates represent the percentages of CD3+ CD8+ cells that produced IL-2, TNF-α, or IFN-γ. (A) The percentage of CD3+ CD8+ cells in lung lymphocytes from naïve, challenged mice or 2X TriVax-vaccinated, challenged mice that expressed IL-2, TNF-α, IFN-γ, TNF-α/IFN-γ−1, OR TNF-α/IFN-γ−1/IL-2− in the presence of M282–90 peptide plus SEM. The cytokine profiles of these cells were determined by expressing each cytokine alone or in combination. Values that are significantly different (P < 0.05) are indicated by a bar and asterisk. Data shown represent one of three experiments with similar results.

The kinetics, magnitude, and quality of the CD8+ T cell response at the effector phase to RSV infection.

**TriVax vaccination results in decreased airway mucin expression and lung inflammation.** Both production of mucus and pulmonary inflammation are key features of RSV disease. Pathological change in lung airways is an important sequela of RSV infection (2, 28). We investigated whether TriVax vaccination can ameliorate RSV-induced inflammation and airway mucin expression. We quantified mucin production in the airways. The 2X TriVax-vaccinated, challenged mice had significantly less airway inflammation. We quantified mucin production in the airways.

**Evaluation of memory CD8+ T cell responses induced by TriVax immunization.** The ability to develop memory T cells after vaccination is essential for protective vaccination against infectious disease and sustenance of the adaptive immune responses. Thus, we investigated the efficacy of TriVax vaccination against RSV A2-line19F at the memory phase. Protection by 2X TriVax was significant but partial at the memory phase (Fig. 5A). The level of protection afforded by 2X TriVax at the memory phase was lower than that at the effector phase (compare Fig. 2A and 5A). On the basis of these results, we initially hypothesized that the number of M282–90 tetramer-positive CD8+ T cells at the memory phase would be lower than that in the effector phase after challenge. Unexpectedly, 40 to 60% tetramer-positive CD3+ CD8+ T cells were observed in 2X TriVax-vaccinated, challenged mice at the memory phase (Fig. 5B). There was no difference in the frequency of tetramer-positive CD8+ T cells between the effector and memory phases of 2X TriVax-vaccinated and challenged mice (compare Fig. 2B and 5B). No weight loss was detected in both groups at the memory phase (Fig. 5C). We then hypothesized that there is some defect in cytokine production by Ag-specific CD8+ T cells at the memory phase following 2X TriVax vaccination and challenge. We measured cytokine production at day 4 p.i. by ICS. First, we compared the ratio of percent IFN-γ-expressing to percent tetramer-positive CD8+ T cells at the effector phase to the memory phase. As shown in Fig. 6A, 62.1% of CD8+ T cells were tetramer positive (Tet+) and 52.5% of CD8+ T cells were IFN-γ+ during the effector phase, and the ratio of Tet+ to IFN-γ+ was therefore 84%. In contrast, during the memory phase, 55.8% of CD8+ T cells were Tet− but only 13.9% of CD8+ T cells were IFN-γ+ (25% ratio of Tet+ to IFN-γ+). We measured IFN-γ, TNF-α, IL-2, TNF-α/IFN-γ−1, OR TNF-α/IFN-γ−1/IL-2− expression to characterize the quality of M282–90 specific CD8+ T cell responses elicited by 2X TriVax vaccination at the memory phase. We thus observed significantly lower lung CD8+ T cell cytokine expression at the memory phase compared to the effector phase following 2X TriVax vaccination and RSV challenge (Fig. 6B). These data suggest that waning protection against RSV infection at the memory phase following 2X TriVax vaccination is due to the generation of memory CD8+ T cells that express relatively low levels of antiviral cytokines.

**DISCUSSION**

In this study, we demonstrated that a peptide vaccination strategy (TriVax) consisting of a comixture of an RSV M282–90 peptide, the TLR3 agonist poly(I:C), and a costimulatory anti-CD40 MAb generated high-quality anti-RSV cytotoxic T lymphocytes (CTL) and protected against RSV A2-line19F strain infection and RSV disease parameters in BALB/c mice. A higher percentage of M282–90-specific CD8+ T cells induced by 2X TriVax vaccination and RSV infection expressed IFN-γ compared to CD8+ T cells induced by no vaccination and RSV infection. Thus, TriVax vaccination
Vaccine-Elicited CD8 T Cells Protect against RSV

Our study provides additional evidence that IFN-γ plays a protective role in RSV disease. As the functional capacities for multiple cytokine expression of virus-specific CD8$^+$ T cells is an important factor for virus control, we hypothesize that the generation of functionally high-quality CD8$^+$ T cells is crucial to determine protective versus pathological roles of CD8$^+$ T cells (8). In order to define the function of CD8$^+$ T cell responses elicited by TriVax, we measured a common set of cytokines, IFN-γ, TNF-α, and IL-2, via polychromatic ICS assay. We found that complete protection against RSV correlated with the rapid appearance of triple positive (IFN-γ TNF-α IL-2) RSV-specific CD8$^+$ T cells.
mechanisms are still unknown. The impaired function of CD8+ T lymphocytes after challenge. BALB/c mice (n = 6) were challenged with A2-line19F at day 42 postbooster. Lungs were harvested on day 4 p.i., and infectious RSV was titrated by plaque assay. The horizontal line depicts the limit of detection. (B) Enumeration of M282–90-specific CD8+ T lymphocytes after challenge. BALB/c mice (n = 6) were challenged with A2-line19F at day 42 postbooster. Lung lymphocytes were isolated on day 4 p.i. and stained with anti-CD3, anti-CD8, and M282–90 tetramer. (C) Weight loss. BALB/c mice (five mice per group) were unvaccinated or vaccinated with M282–90 2X TriVax and challenged with RSV A2-line19F at day 6 postbooster (effector phase) or at day 42 postbooster (memory phase). Lung lymphocytes were isolated on day 4 p.i. and incubated in the presence of M282–90 peptide (1 μg/sample) for ICS assay. Tetramer staining was performed separately from ICS staining. (B) Cytokine profiles of effector and memory CD8+ T cells. The percentage of CD3+ CD8+ T cells in lung lymphocytes from TriVax-vaccinated, challenged mice that expressed IL-2, TNF-α, IFN-γ, TNF-α, IFN-γ, or TNF-α IFN-γ IL-2 in the presence or absence of M282–90 peptide plus SEM. The cytokine profiles of these cells were determined by expressing each cytokine alone or in combination. Values that are significantly different (P < 0.05) are indicated by a bar and asterisk. Data show one of three experiments with equivalent results.

The generation of robust and long-lasting CD8+ T cell responses against RSV may enhance the development of a successful vaccine. Ag-specific CD8+ T cells persist 35 days in the respiratory tracts of mice following influenza virus infection (55). However, RSV-specific CD8+ T cells are short-lived in mice following primary infection, suggesting protective CD8+ T cell-mediated immunity wanes relatively quickly (15, 30). As we demonstrated, TriVax vaccination successfully generated RSV-specific memory CD8+ T cells in lungs in terms of tetramer-positive responses. Indeed, RSV-specific tetramer responses elicited by TriVax at the memory phase were equivalent to those at the effector phase. However, memory CD8+ T cells elicited by TriVax peptide vaccination were moderately antiviral. Compared to CD8+ T cells during the effector phase, pulmonary memory CD8+ T cells during the memory phase following TriVax vaccination and RSV challenge produced less IFN-γ, TNF-α, IL-2, TNF-α/IFN-γ, and TNF-α/IFN-γ/IL-2.

Currently, it is unclear why memory CD8+ T cells generated by TriVax produced lower cytokine levels. This could be why memory CD8+ T cells are less effective in protection compared to effector CD8+ T cells in our model. The purpose of anti-CD40 is to provide a strong costimulatory signal to APCs to facilitate T cell-APC interaction by mimicking CD40-CD40L interaction. CD40-CD40L interaction is as an important component of generating memory CD8+ T cells (10). Although TriVax components contain anti-CD40 that could resemble CD4 help function, it is possible that the effect was not sufficient to generate highly effective memory CD8+ T cells. CD8+ T cells generated in the absence of CD4+ T cell help show impaired protective function and loss of proliferative capacity (27, 49, 52). In contrast, CD4+ T cell help is not crucial for maintaining memory CD8+ T cells in some experimental models (1, 36). The role of CD4+ T cell help in the maintenance of CD8+ memory T cells in RSV models is currently unknown, and we are working on this using modified TriVax vaccination strategies.

Several studies have shown that virus infection alters function of CD8+ T cells in the lungs (20, 24). Although this phenomenon has been observed in multiple viral models, the underlying mechanisms are still unknown. The impaired function of CD8+ T cells in the lung during virus infection has been proposed to be the consequence of virus-induced changes in the lung environment (24). Thus, it appears that T cell suppressive environments are present in local lung tissue. Interestingly, Fulton et al. reported that impaired cytokine production was rescued by exogenous peptide-pulsed antigen-presenting cells (APCs) (20). This result suggested the possibility that APCs in the lungs were not providing sufficient activation signal to T cells for cytokine production. In our model during the effector phase following TriVax vaccination, it seems that the combination of TLR signaling and CD40-CD40L (CD40 ligand) interaction acts like an exogenous APC to reverse a suppressive environment in the lung (7, 26). Clearly, additional mechanistic studies are required to elucidate the underlying mechanism of how TriVax vaccination rescued impaired cytokine production induced by RSV infection.
Although T cells responding to RSV correlate with protection, induction of neutralizing antibody is a major goal of RSV vaccination (11, 35, 37, 45, 55). Neutralizing antibodies (nAb) can prevent RSV infection, but no vaccine has elicited these sufficiently (22, 45). The most effective strategy to provide robust protection against reinfection and disease may be the combination of long-lived antibody and T cell immunity (9). Different combinations of adjuvants with RSV and T cell antigens may be an alternative approach to induce B cell immunity in addition to T cell immunity. The NS1 protein of RSV inhibits CD8+ and CD4+ T cell proliferation (41). Inhibition of CD4+ T cell responses by RSV infection may blunt CD4+ T cell help to B cells and CD8+ T cells. Therefore, elucidation of mechanisms to stimulate CD4+ T cell responses for RSV immunity may contribute to protection via CTL and/or Ab.

In summary, RSV-specific CD8+ T cells have the potential to protect against RSV-induced lung disease, but mechanisms and limits of cell-mediated immunity (CMI) to RSV are incompletely defined. TriVax peptide vaccination is a useful tool to define RSV-specific T cells induced by a model Ag-specific T cell vaccine. In fact, identification and characterization of RSV epitopes in humans is an expanding area of research to design effective RSV vaccines (4). The N protein has been considered a major target for memory CD8+ T cell responses (21). Here, we challenged mice with RSV during the acute phase as well as the memory phase of the T cell response. Further studies will be required to define the central and effector memory phenotypes and functions of TriVax-induced RSV-specific CD8+ T cells in BALB/c mice. Our findings support the notion that generation of high-quality antiviral CD8+ T cells will contribute to RSV vaccines.

ACKNOWLEDGMENTS

We thank the Emory Children’s Pediatric Research Center flow cytometry core and biosistatistics core, which are supported by Children’s Healthcare of Atlanta (CHOA). We thank Carla Shoffeitt (CHOA) for histology technical assistance and Murali Kaja (Emory University) for critical review of the manuscript. We also thank the NIAID Tetramer Facility for providing valuable monomers.

This work was supported by the following grants: NIH 1R01AI087798, NIH 1U19AI095227, an Emory University Research Committee and Atlanta Clinical & Translational Science Institute Pilot Grant, and a Georgia Research Alliance (GRA) Next Generation Vaccines and Therapeutics Collaborative Planning Grant (M. L. Moore), as well as an Emory Egleston Children Research Center (EECRC) grant and an American Federation of Aging Research (AFAR) grant (S. Lee).

REFERENCES

30. Kulkarni AB, et al. 1995. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of